Soleno Therapeutics, Inc. (SLNO) Stock

SLNO logo

Soleno Therapeutics, Inc.

SLNO
Healthcare

Company profile

In Q3 2025 (the quarter ended September 30, 2025) revenue was $66.02 million. In Q3 2025 it reported net income of $26.01 million, against a net loss of $76.62 million a year earlier.

What stands out

  • It reported a net loss in each of its last 5 fiscal years; the loss widened from $38.99 million in fiscal year 2023 to $175.85 million in fiscal year 2024.
  • It reported no revenue in fiscal year 2024 or in the 4 fiscal years before; it spent $78.57 million on research and development.

Figures from company filings; latest fiscal year ended December 31, 2024.

Largest shareholders

  • Fidelity Management & Research Co. LLC11.21%
  • Wellington Trust Co., NA8.57%
  • Wellington Management Co. LLP8.57%
  • BlackRock Advisors LLC6.75%
  • SSgA Funds Management, Inc.5.19%

Share of the company, as of May 19, 2026

What companies are similar to Soleno Therapeutics?

Listed companies of a similar size in the same industry (obesity treatment pharmaceuticals) include Rhythm Pharmaceuticals, Inc. (RYTM), Structure Therapeutics Inc. (GPCR), BioAge Labs, Inc. (BIOA), Aardvark Therapeutics, Inc. (AARD).

Has Soleno Therapeutics made a profit in recent years?

Net income by fiscal year: FY2020, a loss of $24.64 million; FY2021, a loss of $30.91 million; FY2022, a loss of $24.07 million; FY2023, a loss of $38.99 million; FY2024, a loss of $175.85 million. It reported a net loss in each of these 5 years.

How much does Soleno Therapeutics spend on research and development?

Research and development by fiscal year: FY2020, $23.19 million; FY2021, $21.45 million; FY2022, $15.27 million; FY2023, $25.19 million; FY2024, $78.57 million.

Company Information

SectorHealthcare
IndustryObesity Treatment Pharmaceuticals
FoundedAug 25, 1999
IPO DateNov 14, 2014
IPO StatusPublic
FoundersAnish Bhatnagar
ExchangeNasdaqCM
TimezoneAmerica/New_York (EST)

Contact & Links

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Soleno Therapeutics, Inc. (SLNO)”, data as of May 19, 2026, https://dataporium.tech/stocks/SLNO

LinkedInLinkedInXXYouTubeYouTube